Physician profile
Amy Tracy
NPI 1679941322
$7,090.24
in general payments reported to CMS, 2019-2025
24 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $1,002 · 2023: $2,861 · 2024: $1,774 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169 · Travel and Lodging: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.92 |
| Travel and Lodging | $1,098.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,973.71 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,001.27 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $746.00 | 2021-2024 | Caplyta |
| Corium, LLC | $680.93 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $642.65 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $318.77 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Idorsia Pharmaceuticals US INC | $314.95 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $286.93 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $237.85 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $231.96 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $162.86 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $104.71 | 2021-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $62.73 | 2022-2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $59.28 | 2023-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $42.87 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $39.18 | 2023 | Ingrezza |
| Noven Therapeutics, LLC | $36.35 | 2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $34.37 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $24.57 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $20.79 | 2025 | Loreev Xr |
| Brainsway USA INC | $18.94 | 2024 | Brainsway Deep Tms System |
| Lundbeck LLC | $17.59 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $16.46 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.52 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.